BAQSIMI® growth offsets weaker 2025 earnings at Amphastar (NASDAQ: AMPH)
Rhea-AI Filing Summary
Amphastar Pharmaceuticals reported fourth-quarter and full-year 2025 results showing modestly lower sales but a sharp drop in profit. Full-year net revenues were
Adjusted non-GAAP net income decreased to
The company generated cash flow from operating activities of
Positive
- Strong BAQSIMI® growth and cash generation: 2025 BAQSIMI® product revenues rose to
$185,358,000 from$126,898,000 , and cash flow from operating activities reached$156,100,000 , supporting continued investment and balance-sheet flexibility. - Pipeline and approval momentum: The company secured FDA approvals for iron sucrose and teriparatide injections and added three novel peptides plus a fully synthetic corticotropin compound, broadening its future product and indication opportunities.
Negative
- Material decline in earnings and margin compression: GAAP net income fell from
$159,519,000 to$98,094,000 , adjusted non-GAAP net income dropped to$156,618,000 from$200,806,000 , and gross profit decreased despite relatively stable revenues. - Rising operating costs: General and administrative expenses increased to
$85,925,000 from$56,720,000 , and research and development rose to$85,844,000 from$73,914,000 , pressuring profitability.
Insights
Profits fell significantly in 2025 despite BAQSIMI®-driven revenue growth and strong operating cash flow.
Amphastar posted slightly lower 2025 net revenues of
Product mix was a major driver. BAQSIMI® revenues surged to
On the positive side, cash flow from operating activities remained strong at
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event Reported):
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of | (Commission File Number) | (I.R.S. Employer Identification |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant's telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||
The | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On February 26, 2026, Amphastar Pharmaceuticals, Inc. issued a press release announcing its financial results for the three months and fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No. | | Description |
99.1 | Press release, dated February 26, 2026, issued by Amphastar Pharmaceuticals, Inc. | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 26, 2026 | Amphastar Pharmaceuticals, Inc. | ||
By: | /s/ WILLIAM J. PETERS | ||
William J. Peters | |||
Chief Financial Officer, Executive Vice President and Treasurer | |||
EXHIBIT 99.1
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025
| - | Net revenues of $183.1 million and $719.9 million, respectively, for the three months and fiscal year ended December 31, 2025 |
| - | GAAP net income of $24.4 million, or $0.51 per share and $98.1 million, or $2.03 per share, respectively, for the fourth quarter and fiscal year |
| - | Adjusted non-GAAP net income of $34.2 million, or $0.73 per share and $156.6 million, or $3.25 per share, respectively, for the fourth quarter and fiscal year |
| - | Company to hold a conference call today at 2:00 p.m. Pacific Time |
RANCHO CUCAMONGA, CA – February 26, 2026 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months and full year ended December 31, 2025.
“2025 underscored Amphastar’s evolution into a company focused on both commercial strength and scientific innovation.” said Dr. Jack Zhang, Amphastar’s President and Chief Executive Officer. “On the commercial side, BAQSIMI® maintained its momentum as a top revenue driver with sustained double-digit growth, while the FDA approvals of our iron sucrose injection and our teriparatide injection demonstrate the depth of our technical capabilities in complex generics and ability to leverage our in-house manufacturing expertise to deliver high-quality, affordable therapies to patients. We also furthered our long-term strategic vision by adding three novel peptides and a fully synthetic corticotropin compound to expand our presence in oncology, ophthalmology, and immunology. As we look ahead to 2026, we remain committed to advancing these programs, securing upcoming approvals, and scaling our U.S. based manufacturing to support the next phase of our growth.”
| | Three Months Ended | | Year Ended |
| ||||||||
| | December 31, | | December 31, |
| ||||||||
| | 2025 | | 2024 | | 2025 | | 2024 |
| ||||
| | (in thousands, except per share data) |
| ||||||||||
Net revenues | | $ | 183,105 | | $ | 186,523 | | $ | 719,887 | | $ | 731,967 | |
GAAP net income | | $ | 24,429 | | $ | 37,964 | | $ | 98,094 | | $ | 159,519 | |
Adjusted non-GAAP net income* | | $ | 34,158 | | $ | 47,237 | | $ | 156,618 | | $ | 200,806 | |
GAAP diluted EPS | | $ | 0.51 | | $ | 0.74 | | $ | 2.03 | | $ | 3.06 | |
Adjusted non-GAAP diluted EPS* | | $ | 0.73 | | $ | 0.92 | | $ | 3.25 | | $ | 3.86 | |
* Adjusted non-GAAP net income and adjusted non-GAAP diluted EPS are non-GAAP financial measures. Please see the discussion in the section entitled “Non-GAAP Financial Measures” and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.
Fourth Quarter Results
| | Three Months Ended | | | | | | | ||||
| | December 31, | | Change | | |||||||
| | 2025 | | 2024 | | Dollars | | % | | |||
| | (in thousands) | | | | |||||||
Product revenues, net: | | | | | | | | | | | | |
BAQSIMI® | | $ | 46,708 | | $ | 41,792 | | $ | 4,916 | | 12 | % |
Primatene MIST® | | | 27,930 | | | 28,935 | | | (1,005) | | (3) | % |
Epinephrine | | | 17,087 | | | 18,698 | | | (1,611) | | (9) | % |
Lidocaine | | | 14,904 | | | 14,397 | | | 507 | | 4 | % |
Glucagon | | | 14,081 | | | 25,619 | | | (11,538) | | (45) | % |
Other products | |
| 62,395 | |
| 57,537 | |
| 4,858 |
| 8 | % |
Total product revenues, net | | $ | 183,105 | | $ | 186,978 | | $ | (3,873) |
| (2) | % |
Other revenues | | | — | | | (455) | | | 455 | | 100 | % |
Total net revenues | | $ | 183,105 | | $ | 186,523 | | $ | (3,418) | | (2) | % |
Changes in product revenues, net as compared to the fourth quarter of the prior year were primarily driven by:
| ● | BAQSIMI® sales increased primarily due to an increase in unit volumes, as a result of our continued marketing efforts in the United States |
| ● | Primatene MIST® sales decreased due to lower unit volumes |
| ● | Epinephrine sales decreased due to lower unit volumes, as well as a lower average selling price of the multi-dose vial product, impacting sales by $2.8 million and $1.5 million, respectively, as a result of increased competition. This trend was partially offset by an increase in unit volumes for our epinephrine pre-filled syringe, as a result of an increase in demand caused by shortages from other suppliers during the quarter |
| ● | Glucagon sales decreased primarily due to a lower average selling price, impacting sales by $10.2 million, as well as a decrease in unit volumes, impacting sales by $1.3 million, as a result of competition and the continued shift to ready to use glucagon products such as BAQSIMI® |
| ● | Other pharmaceutical product sales changes were primarily due to an increase in sales of albuterol of $4.2 million and iron sucrose sales of $2.0 million, which we launched in August 2024 and August 2025, respectively. This increase was partially offset by a decrease in unit volumes of dextrose, primarily due to increased competition |
| ● | Other revenues were zero in the fourth quarter of 2025, as we completed the assumption of distribution responsibilities globally for BAQSIMI® at the beginning of 2025, with all of BAQSIMI® related revenues in the current period being recognized in product revenues, net |
| | Three Months Ended | | | | | | | ||||
| | December 31, | | Change | | |||||||
| | 2025 | | 2024 | | Dollars | | % | | |||
| | (in thousands) | | | | |||||||
Net revenues | | $ | 183,105 | | $ | 186,523 | | $ | (3,418) | | (2) | % |
Cost of revenues | | | 97,435 | | | 99,875 | | | (2,440) | | (2) | % |
Gross profit | | $ | 85,670 | | $ | 86,648 | | $ | (978) | | (1) | % |
as % of net revenues | | | 46.8% | | | 46.5% | | | | | | |
Changes in the cost of revenues and gross margin were primarily driven by:
| ● | Increase in sales of BAQSIMI® and sales of iron sucrose, which we launched in August 2025, as well as cost control efforts across the business |
| ● | This was partially offset by a decrease in pricing of glucagon and our epinephrine multi-dose vial product |
| | Three Months Ended | | | | | | | ||||
| | December 31, | | Change | | |||||||
| | 2025 | | 2024 | | Dollars | | % | | |||
| | (in thousands) | | | | |||||||
Selling, distribution, and marketing | | $ | 10,279 | | $ | 10,424 | | $ | (145) | | (1) | % |
General and administrative | | | 16,471 | | | 12,938 | | | 3,533 | | 27 | % |
Research and development | | | 23,314 | | | 18,142 | | | 5,172 | | 29 | % |
| ● | General and administrative expenses increased primarily due to an increase in salary and personnel-related expenses, legal expenses and expenses related to the implementation of a new ERP system |
| ● | Research and development expenses increased primarily due to an increase in clinical trial expense, primarily related to our insulin and inhalation pipeline products, as well as an increase in material and supplies for our insulin pipeline product |
| | Three Months Ended | | | | | | | ||||
| | December 31, | | Change | | |||||||
| | 2025 | | 2024 | | Dollars | | % | | |||
| | (in thousands) | | | | |||||||
Non-operating expenses: | | | | | | | | | | | | |
Interest income | | $ | 2,423 | | $ | 2,292 | | $ | 131 | | 6 | % |
Interest expense | | | (6,630) | | | (6,425) | | | (205) | | 3 | % |
Other income, net | | | 515 | | | 2,951 | | | (2,436) | | (83) | % |
Total non-operating expenses, net | | $ | (3,692) | | $ | (1,182) | | $ | (2,510) | | 212 | % |
The change in non-operating expenses, net, is primarily due to a change in other income, net, as a result of foreign currency fluctuation, as well as mark-to-market adjustments relating to our interest rate swap contracts during the three months ended December 31, 2025.
Year-End Results
| | Year Ended December 31, | | Change | | |||||||
| | 2025 | | 2024 | | Dollars | | % | | |||
| | (in thousands) | | | | |||||||
Product revenues, net: | | | | | | | | | | | | |
BAQSIMI® | | $ | 185,358 | | $ | 126,898 | | $ | 58,460 | | 46 | % |
Primatene MIST® | | | 108,669 | | | 102,012 | | | 6,657 | | 7 | % |
Epinephrine | | | 70,643 | | | 94,090 | | | (23,447) | | (25) | % |
Glucagon | | | 69,084 | | | 108,319 | | | (39,235) | | (36) | % |
Lidocaine | | | 56,479 | | | 55,854 | | | 625 | | 1 | % |
Other products | |
| 229,654 | |
| 225,641 | |
| 4,013 |
| 2 | % |
Total product revenues, net | | $ | 719,887 | | $ | 712,814 | | $ | 7,073 |
| 1 | % |
Other revenues | | | — | | | 19,153 | | | (19,153) | | (100) | % |
Total net revenues | | $ | 719,887 | | $ | 731,967 | | $ | (12,080) | | (2) | % |
Changes in product revenues, net as compared to the prior fiscal year were primarily driven by:
| ● | BAQSIMI® sales increased primarily due to an increase in unit volumes, as a result of an expanded marketing effort in the United States; total sales of BAQSIMI® grew 12% from the prior year including prior year sales by Eli Lilly and Company, or Lilly, which was accounted for in Other revenues |
| ● | Primatene MIST® sales increased due to an increase in unit volumes driven by our continued marketing efforts |
| ● | Epinephrine sales decreased due to a decrease in unit volumes, impacting sales of $13.4 million, as well as a lower average selling price, which impacted sales of $10.0 million, primarily as a result of increased competition for our multi-dose vial product |
| ● | Glucagon sales decreased primarily due to a lower average selling price, impacting sales by $24.3 million, as well as a decrease in unit volumes, impacting sales by $14.9 million, as a result of competition and the continued shift to ready to use glucagon products such as BAQSIMI® |
| ● | Other pharmaceutical product sales changes were primarily due to an increase in sales of albuterol of $14.7 million and iron sucrose sales of $4.4 million, which were launched in August 2024 and August 2025, respectively, as well as an increase in sales of sodium bicarbonate and atropine due to an increase in demand caused by other supplier shortages. This increase was partially offset by a decrease in sales of enoxaparin of $9.9 million and dextrose of $9.6 million due to increased competition |
| ● | Other revenues were zero in the year ended December 31, 2025 as we completed the assumption of distribution responsibilities globally for BAQSIMI® at the beginning of 2025, with all of BAQSIMI® related revenues in the current period being recognized in Product revenues, net. The other revenues in the year ended December 31, 2024 consisted of $19.2 million in BAQSIMI® sales made by Lilly on our behalf under the Transition Service Agreement (“TSA”), and was net of $18.4 million in cost of sales and other expenses |
| | Year Ended December 31, | | Change | | |||||||
| | 2025 | | 2024 | | Dollars | | % | | |||
| | (in thousands) | | | | |||||||
Net revenues | | $ | 719,887 | | $ | 731,967 | | $ | (12,080) | | (2) | % |
Cost of revenues | | | 363,830 | | | 358,112 | | | 5,718 | | 2 | % |
Gross profit | | $ | 356,057 | | $ | 373,855 | | $ | (17,798) | | (5) | % |
as % of net revenues | | | 49.5% | | | 51.1% | | | | | | |
Changes in the cost of revenues and gross margin were primarily driven by:
| ● | Decrease in other revenues related to Lilly’s sales of BAQSIMI® under the TSA, which were recorded net of cost of sales and other expenses; as we assumed distribution of BAQSIMI® to all of our customers by the beginning of 2025. We recorded those sales in product revenues and cost of sales separately |
| ● | Lower pricing of glucagon and our epinephrine multi-dose vial product, both of which are higher-margin products |
| ● | Cost control efforts across the business partially offset the impact of pricing declines |
| | Year Ended December 31, | | Change | | |||||||
| | 2025 | | 2024 | | Dollars | | % | | |||
| | (in thousands) | | | | |||||||
Selling, distribution, and marketing | | $ | 43,885 | | $ | 37,802 | | $ | 6,083 | | 16 | % |
General and administrative | | | 85,925 | | | 56,720 | | | 29,205 | | 51 | % |
Research and development | | | 85,844 | | | 73,914 | | | 11,930 | | 16 | % |
| ● | Selling, distribution, and marketing expenses increased primarily due to the expansion of our sales and marketing efforts related to BAQSIMI®, including expenses related to our co-promotion contract with MannKind, and sales efforts related to Primatene MIST® |
| ● | General and administrative expenses increased primarily due to a legal settlement, which increased expenses by $23.1 million |
| ● | Research and development expenses increased primarily due to the $6.0 million upfront payment for the licensing agreement that we entered into with Nanjing Anji Biotechnology Co., Ltd. (“Anji”), during the year. Additionally, we had an increase in clinical trial expense, primarily related to our insulin and inhalation pipeline products, as well as an increase in depreciation expense. This was partially offset by a decrease in materials and supply expenses |
| | Year Ended December 31, | | Change | | |||||||
| | 2025 | | 2024 | | Dollars | | % | | |||
| | (in thousands) | | | | |||||||
Non-operating expenses: | | | | | | | | | | | | |
Interest income | | $ | 8,679 | | $ | 10,612 | | $ | (1,933) | | (18) | % |
Interest expense | | | (25,481) | | | (30,343) | | | 4,862 | | (16) | % |
Other income, net | | | 23 | | | 4,076 | | | (4,053) | | (99) | % |
Total non-operating expenses, net | | $ | (16,779) | | $ | (15,655) | | $ | (1,124) | | 7 | % |
The change in non-operating expenses, net is primarily a result of:
| ● | A decrease in interest income resulting from a decrease in interest rates on our cash and investments accounts |
| ● | A decrease in interest expense as a result of the repayment of the mortgage loan with East West Bank, as well as the accretion of the interest on the deferred payment for BAQSIMI®, both of which were paid in full in June 2024 |
| ● | A change to other income, net, primarily as a result of foreign currency fluctuation, as well as mark-to-market adjustments relating to our interest rate swap contracts during the year ended December 31, 2025 |
Cash flow provided by operating activities for the year ended December 31, 2025, was $156.1 million.
Pipeline Information
The Company currently has one abbreviated new drug application (“ANDA”) and one biosimilar insulin candidate filed with the FDA targeting products with a combined market size exceeding $1.7 billion, along with two biosimilar products in development targeting products with a market size exceeding $3.7 billion, and two generic products in development targeting products with a market size of over $1 billion. This market information is based on IQVIA data for the 12 months ended December 31, 2025. The Company is developing multiple proprietary products with injectable, topical and intranasal dosage forms.
The Company’s proprietary pipeline also includes four recently in-licensed products including three proprietary peptides targeting oncology and ophthalmology indications, and a fully synthetic corticotropin compound designed to address inflammatory and autoimmune conditions.
Conference Call Information
The Company will hold a conference call to discuss its financial results today, February 26, 2026, at 2:00 p.m. Pacific Time.
To access the conference call, dial toll-free (877) 407-0989 or (201) 389-0921 for international callers, ten minutes before the conference.
The call can also be accessed on the Investors page on the Company’s website at www.amphastar.com.
Non-GAAP Financial Measures
To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles (“GAAP”), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) and (ii) Adjusted non-GAAP diluted EPS, which generally excludes amortization expense, share-based compensation, impairment charges, expenses related to our acquisition of BAQSIMI®, certain debt issuance costs, legal settlements, and other one-time events in order to supplement investors’ and other readers’ understanding and assessment of the Company’s financial performance because the Company’s management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.
Market Data
This press release contains market data that we obtained from industry sources. These sources do not guarantee the accuracy or completeness of the information. Although we believe that our industry sources are reliable, we do not independently verify the information. The market data may include projections that are based on a number of other
projections. While we believe these assumptions to be reasonable and sound as of the date of this press release, actual results may differ from the projections.
About Amphastar Pharmaceuticals, Inc.
Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient, or API products. Most of the Company’s finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com.
Amphastar’s logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVY®, Amphadase®, and Cortrosyn®, are the property of Amphastar.
Forward-Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high-quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar’s historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission (“SEC”), including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 7, 2025, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 6, 2025, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact Information:
Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416
Table I
Amphastar Pharmaceuticals, Inc.
Consolidated Statement of Operations
(in thousands, except per share data)
| | Three Months Ended | | Year Ended |
| ||||||||
| | December 31, | | December 31, |
| ||||||||
| | 2025 | | 2024 | | 2025 | | 2024 |
| ||||
Net revenues: | | | | | | | | | | | | | |
Product revenues, net | | $ | 183,105 | | $ | 186,978 | | $ | 719,887 | | $ | 712,814 | |
Other revenues | | | — | | | (455) | | | — | | | 19,153 | |
Total net revenues | | | 183,105 | | | 186,523 | | | 719,887 | | | 731,967 | |
| | | | | | | | | | | | | |
Cost of revenues | |
| 97,435 | | | 99,875 | | | 363,830 | | | 358,112 | |
Gross profit | |
| 85,670 | |
| 86,648 | |
| 356,057 | |
| 373,855 | |
| | | | | | | | | | | | | |
Operating expenses: | | | | | | | | | | | | | |
Selling, distribution, and marketing | |
| 10,279 | | | 10,424 | | | 43,885 | | | 37,802 | |
General and administrative | |
| 16,471 | | | 12,938 | | | 85,925 | | | 56,720 | |
Research and development | |
| 23,314 | | | 18,142 | | | 85,844 | | | 73,914 | |
Total operating expenses | |
| 50,064 | |
| 41,504 | |
| 215,654 | |
| 168,436 | |
| | | | | | | | | | | | | |
Income from operations | |
| 35,606 | |
| 45,144 | |
| 140,403 | |
| 205,419 | |
| | | | | | | | | | | | | |
Non-operating expenses: | | | | | | | | | | | | | |
Interest income | | | 2,423 | | | 2,292 | | | 8,679 | | | 10,612 | |
Interest expense | | | (6,630) | | | (6,425) | | | (25,481) | | | (30,343) | |
Other income, net | | | 515 | | | 2,951 | | | 23 | | | 4,076 | |
Total non-operating expenses, net | |
| (3,692) | | | (1,182) | | | (16,779) | | | (15,655) | |
| | | | | | | | | | | | | |
Income before income taxes | |
| 31,914 | |
| 43,962 | |
| 123,624 | |
| 189,764 | |
Income tax provision | |
| 7,485 | | | 5,998 | | | 25,530 | | | 29,672 | |
Income before equity in losses of unconsolidated affiliate | | | 24,429 | | | 37,964 | | | 98,094 | | | 160,092 | |
| | | | | | | | | | | | | |
Equity in losses of unconsolidated affiliate | | | — | | | — | | | — | | | (573) | |
| | | | | | | | | | | | | |
Net income | | $ | 24,429 | | $ | 37,964 | | $ | 98,094 | | $ | 159,519 | |
| | | | | | | | | | | | | |
Net income per share: | | | | | | | | | | | | | |
Basic | | $ | 0.53 | | $ | 0.79 | | $ | 2.10 | | $ | 3.29 | |
Diluted | | $ | 0.51 | | $ | 0.74 | | $ | 2.03 | | $ | 3.06 | |
| | | | | | | | | | | | | |
Weighted-average shares used to compute net income per share: | | | | | | | | | | | | | |
Basic | | | 45,907 | | | 47,975 | | | 46,743 | | | 48,429 | |
Diluted | | | 47,164 | | | 51,310 | | | 48,215 | | | 52,058 | |
Table II
Amphastar Pharmaceuticals, Inc.
Consolidated Balance Sheets
(in thousands, except share data)
| | December 31, | | December 31, | ||
| | 2025 | | 2024 | ||
ASSETS | | | | | | |
Current assets: | | | | | | |
Cash and cash equivalents | | $ | 170,177 | | $ | 151,609 |
Restricted cash | | | 235 | | | 235 |
Short-term investments | | | 112,635 | | | 70,036 |
Restricted short-term investments | |
| 2,200 | | | 2,200 |
Accounts receivable, net | |
| 143,560 | | | 136,289 |
Inventories | |
| 176,890 | | | 153,741 |
Income tax refunds and deposits | |
| 17,167 | | | 1,747 |
Prepaid expenses and other assets | |
| 13,152 | | | 18,214 |
Total current assets | |
| 636,016 | |
| 534,071 |
| | | | | | |
Property, plant, and equipment, net | |
| 310,567 | | | 297,345 |
Finance lease right-of-use assets | | | 221 | | | 383 |
Operating lease right-of-use assets | | | 42,931 | | | 46,899 |
Goodwill and intangible assets, net | |
| 565,965 | | | 590,660 |
Long-term investments | | | — | | | 10,996 |
Other assets | |
| 31,135 | | | 25,992 |
Deferred tax assets | |
| 42,464 | | | 71,124 |
Total assets | | $ | 1,629,299 | | $ | 1,577,470 |
| | | | | | |
LIABILITIES AND STOCKHOLDERS' EQUITY | | | | | | |
Current liabilities: | | | | | | |
Accounts payable and accrued liabilities | | $ | 148,348 | | $ | 157,057 |
Income taxes payable | |
| 239 | |
| 9,664 |
Current portion of long-term debt | |
| 1,641 | |
| 234 |
Current portion of operating lease liabilities | | | 7,928 | | | 6,804 |
Total current liabilities | |
| 158,156 | |
| 173,759 |
| | | | | | |
Long-term reserve for income tax liabilities | |
| 5,926 | | | 6,957 |
Long-term debt, net of current portion and unamortized debt issuance costs | |
| 608,749 | | | 601,630 |
Long-term operating lease liabilities, net of current portion | | | 37,684 | | | 41,881 |
Other long-term liabilities | |
| 29,979 | | | 20,945 |
Total liabilities | |
| 840,494 | |
| 845,172 |
Commitments and contingencies | | | | | | |
Stockholders’ equity: | | | | | | |
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding | |
| — | |
| — |
Common stock: par value $0.0001; 300,000,000 shares authorized; 61,779,883 and 45,645,497 shares issued and outstanding, respectively, as of December 31, 2025 and 60,847,124 and 47,617,691 shares issued and outstanding, respectively, as of December 31, 2024 | |
| 6 | | | 6 |
Additional paid-in capital | |
| 535,380 | | | 505,400 |
Retained earnings | |
| 666,881 | | | 568,787 |
Accumulated other comprehensive loss | |
| (5,314) | | | (9,181) |
Treasury stock | |
| (408,148) | | | (332,714) |
Total stockholders' equity | | | 788,805 | | | 732,298 |
Total liabilities and stockholders’ equity | | $ | 1,629,299 | | $ | 1,577,470 |
Table III
Amphastar Pharmaceuticals, Inc.
Reconciliation of Non-GAAP Measures
(in thousands, except per share data)
| | Three Months Ended | | Year Ended | ||||||||
| | December 31, | | December 31, | ||||||||
| | 2025 | | 2024 | | 2025 | | 2024 | ||||
| | | | | | | | | | | | |
GAAP net income | | $ | 24,429 | | $ | 37,964 | | $ | 98,094 | | $ | 159,519 |
Adjusted for: | | | | | | | | | | | | |
Intangible asset amortization | |
| 6,270 | |
| 6,179 | |
| 25,048 | |
| 24,718 |
Share-based compensation | |
| 6,205 | |
| 5,632 | |
| 27,277 | |
| 24,368 |
Expenses related to BAQSIMI® acquisition | | | — | | | — | | | — | | | 3,651 |
Litigation provision | | | — | | | — | | | 23,147 | | | — |
Income tax provision on pre-tax adjustments | |
| (2,746) | |
| (2,538) | |
| (16,948) | |
| (11,450) |
Adjusted non-GAAP net income | | $ | 34,158 | | $ | 47,237 | | $ | 156,618 | | $ | 200,806 |
| | | | | | | | | | | | |
Adjusted non-GAAP net income per share: | | | | | | | | | | | | |
Basic | | $ | 0.75 | | $ | 0.99 | | $ | 3.35 | | $ | 4.15 |
Diluted | | $ | 0.73 | | $ | 0.92 | | $ | 3.25 | | $ | 3.86 |
| | | | | | | | | | | | |
Weighted-average shares used to compute adjusted non-GAAP net income per share: | | | | | | | | | | | | |
Basic | |
| 45,907 | |
| 47,975 | |
| 46,743 | |
| 48,429 |
Diluted | |
| 47,164 | |
| 51,310 | |
| 48,215 | |
| 52,058 |
| | Three Months Ended December 31, 2025 | ||||||||||||||||
| | | | | | | | | | | | | | |||||
| | | | Selling, | | General | | Research | | Non-operating | | | ||||||
| | Cost of | | distribution | | and | | and | | (expenses) | | Income | ||||||
| | revenue | | and marketing | | administrative | | development | | income, net | | tax provision | ||||||
GAAP | | $ | 97,435 | | $ | 10,279 | | $ | 16,471 | | $ | 23,314 | | $ | (3,692) | | $ | 7,485 |
Intangible asset amortization | | | (6,250) | | | — | | | (1) | | | (19) | | | — | | | — |
Share-based compensation | | | (1,193) | | | (290) | | | (4,142) | | | (580) | | | — | | | — |
Income tax provision on pre-tax adjustments | | | — | | | — | | | — | | | — | | | — | | | 2,746 |
Non-GAAP | | $ | 89,992 | | $ | 9,989 | | $ | 12,328 | | $ | 22,715 | | $ | (3,692) | | $ | 10,231 |
| | Three Months Ended December 31, 2024 | ||||||||||||||||
| | | | | | | | | | | | | | |||||
| | | | Selling, | | General | | Research | | Non-operating | | | ||||||
| | Cost of | | distribution | | and | | and | | (expenses) | | Income | ||||||
| | revenue | | and marketing | | administrative | | development | | income, net | | tax provision | ||||||
GAAP | | $ | 99,875 | | $ | 10,424 | | $ | 12,938 | | $ | 18,142 | | $ | (1,182) | | $ | 5,998 |
Intangible asset amortization | | | (6,160) | | | — | | | — | | | (19) | | | — | | | — |
Share-based compensation | | | (1,159) | | | (286) | | | (3,682) | | | (505) | | | — | | | — |
Income tax provision on pre-tax adjustments | | | — | | | — | | | — | | | — | | | — | | | 2,538 |
Non-GAAP | | $ | 92,556 | | $ | 10,138 | | $ | 9,256 | | $ | 17,618 | | $ | (1,182) | | $ | 8,536 |
| | Year Ended December 31, 2025 | ||||||||||||||||
| | | | | | | | | | | | | | |||||
| | | | Selling, | | General | | Research | | Non-operating | | | ||||||
| | Cost of | | distribution | | and | | and | | (expenses) | | Income | ||||||
| | revenue | | and marketing | | administrative | | development | | income, net | | tax provision | ||||||
GAAP | | $ | 363,830 | | $ | 43,885 | | $ | 85,925 | | $ | 85,844 | | $ | (16,779) | | $ | 25,530 |
Intangible asset amortization | | | (24,968) | | | — | | | (3) | | | (77) | | | — | | | — |
Share-based compensation | | | (6,205) | | | (1,215) | | | (16,919) | | | (2,938) | | | — | | | — |
Litigation provision | | | — | | | — | | | (23,147) | | | — | | | — | | | — |
Income tax provision on pre-tax adjustments | | | — | | | — | | | — | | | — | | | — | | | 16,948 |
Non-GAAP | | $ | 332,657 | | $ | 42,670 | | $ | 45,856 | | $ | 82,829 | | $ | (16,779) | | $ | 42,478 |
| | Year Ended December 31, 2024 | ||||||||||||||||
| | | | | | | | | | | | | | |||||
| | | | Selling, | | General | | Research | | Non-operating | | | ||||||
| | Cost of | | distribution | | and | | and | | (expenses) | | Income | ||||||
| | revenue | | and marketing | | administrative | | development | | income, net | | tax provision | ||||||
GAAP | | $ | 358,112 | | $ | 37,802 | | $ | 56,720 | | $ | 73,914 | | $ | (15,655) | | $ | 29,672 |
Intangible asset amortization | | | (24,639) | | | — | | | (4) | | | (75) | | | — | | | — |
Share-based compensation | | | (5,742) | | | (1,063) | | | (14,921) | | | (2,642) | | | — | | | — |
Expenses related to BAQSIMI® acquisition | | | — | | | — | | | — | | | — | | | 3,651 | | | — |
Income tax provision on pre-tax adjustments | | | — | | | — | | | — | | | — | | | — | | | 11,450 |
Non-GAAP | | $ | 327,731 | | $ | 36,739 | | $ | 41,795 | | $ | 71,197 | | $ | (12,004) | | $ | 41,122 |
FAQ
How did Amphastar (AMPH) perform financially in full-year 2025?
What were Amphastar (AMPH) fourth-quarter 2025 results?
How important was BAQSIMI® to Amphastar’s 2025 revenue mix?
What happened to Amphastar’s margins and operating expenses in 2025?
What is Amphastar’s liquidity and cash flow position after 2025?
What pipeline and regulatory developments did Amphastar (AMPH) highlight?
Did Amphastar (AMPH) provide non-GAAP financial measures for 2025?
Filing Exhibits & Attachments
4 documentsPress Releases
